"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
For Intravenous or Intramuscular Use
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β (Z)]]. It has the following structure:
The empirical formula is C22H32N6O12S2, representing a molecular weight of 636.6.
CEPTAZ is a sterile, dry mixture of ceftazidime pentahydrate and L-arginine. The L-arginine is at a concentration of 349 mg/g of ceftazidime activity. CEPTAZ (ceftazidime) dissolves without the evolution of gas. The product contains no sodium ion. Solutions of CEPTAZ (ceftazidime) range in color from light yellow to amber, depending on the diluent and volume used. The pH of freshly constituted solutions usually ranges from 5 to 7.5.
Last reviewed on RxList: 11/16/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Ceptaz Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.